CD4 and Kaposi's sarcoma: Among HAART users, CD4 cell count at treatment initiation below 50 cells μl−1 (HR vs ⩾350 cells μl−1, 5.36; 95% CI, 2.08–13.80) (data not shown) was even more strongly associated with KS risk than CD4 cell count at enrolment.